The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukaemia: a retrospective non-interventional post-authorisation safety study in Europe.
Sign Up to like & getrecommendations! Published in 2022 at "Hematological oncology"
DOI: 10.1002/hon.2978
Abstract: Rapid infusion (RI) of the rituximab biosimilar CT-P10 is currently only an approved treatment regimen for the treatment of rheumatoid arthritis. Although both CT-P10 and reference rituximab are known to be frequently administered using a… read more here.
Keywords: safety; effectiveness; p10; p10 patients ... See more keywords